Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
: Hypersensitivity reactions (HSRs) to iodinated contrast media (ICM), both immediate and non-immediate, pose clinical challenges despite using low-osmolality agents. This review aims to summarize current diagnostic approaches, cross-reactivity patterns, and the debated role of premedication. : A narrative review was conducted using PubMed (2014-2024), selecting studies on ICM-related HSRs, focusing on skin and in vitro testing, drug provocation tests (DPTs), cross-reactivity, and premedication. : Skin tests show limited sensitivity, especially for non-immediate reactions. Cross-reactivity among ICMs is common but unpredictable. DPTs are the diagnostic gold standard but lack standardized protocols. Premedication is frequently used, though its efficacy remains uncertain. : The management of ICM hypersensitivity is limited by diagnostic gaps and insufficient evidence on premedication. Standardized protocols and prospective studies are needed to improve patient safety and guide clinical decisions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12155178 | PMC |
| http://dx.doi.org/10.3390/healthcare13111308 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting FSP1 to induce ferroptosis in chromophobe renal cell carcinoma.
Oncogene
September 2025
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
There are no proven therapies for metastatic or unresectable Chromophobe Renal Cell Carcinoma (ChRCC). ChRCC is characterized by high glutathione levels and hypersensitivity to ferroptosis, an iron-dependent form of cell death characterized by peroxidation of polyunsaturated fatty acids. The underlying mechanisms leading to ferroptosis hypersensitivity are unknown.
View Article and Find Full Text PDFPharmacogenetics in oncology: Unveiling its potential in treatment personalization and beyond.
Bull Cancer
September 2025
Department of Pathology and Medical Biology, Cancer Genetics Laboratory, Gustave Roussy, Villejuif, France.
The effectiveness and tolerability of medicines can vary considerably from person to person, even at the same dose. This variation is influenced by many factors, including constitutional genetic characteristics. In fact, some people have genetic variations that are common and neutral in the population, known as polymorphisms, which can affect drug metabolism or make them more susceptible to certain adverse effects.
View Article and Find Full Text PDFMultiomics approach to evaluating personalized biomarkers of allergen immunotherapy.
J Allergy Clin Immunol
September 2025
National Heart and Lung Institute, Imperial College London, London, United Kingdom; Frankland and Kay Allergy Centre, UK NIHR Imperial Biomedical Research Centre, United Kingdom.
Recent advancements in genomics and "omic" technologies have ushered in a transformative era referred to as personalized or precision medicine. This innovative approach considers the unique genetic profiles of individuals, along with a range of variability factors, to devise tailored disease treatments and prevention strategies that cater to the distinct needs of each patient. Although the terms personalized medicine and precision medicine are frequently utilized interchangeably, it is essential to delineate the subtle distinctions between them.
View Article and Find Full Text PDFBiasing G protein βγ subunit downstream signaling enhances the analgesic effects of endogenous opioid receptor agonists during nitroglycerin-induced thermal hypersensitivity.
Mol Pharmacol
August 2025
Department of Pharmacology, University of Michigan, Ann Arbor, Michigan.
μ-Opioid receptor (MOR) agonists are a mainstay in acute pain management. However, they also produce adverse effects and are frequently misused, increasing susceptibility for opioid use disorder. Thus, a strategy for improving the safety of opioid analgesics is needed.
View Article and Find Full Text PDF